Anastasia

Novel Drugs in Follicular Lymphoma

Antonella Anastasia and Giuseppe Rossi

SC Ematologia e Dipartimento di Oncologia Clinica, A.O. Spedali Civili, 25123 Brescia, Italy.

Corresponding author: Antonella Anastasia. SC Ematologia e Dipartimento di Oncologia Clinica, A.O. Spedali Civili, 25123 Brescia, Italy. E-mail: antonella.anastasia@gmail.com

Published: November 1, 2016
Received: August 12, 2016
Accepted: October 25, 2016
Mediterr J Hematol Infect Dis 2016, 8(1): e2016061, DOI 10.4084/MJHID.2016.061
This article is available on PDF format at:

This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Abstract

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma and constitutes 15% to 30% of lymphoma diagnoses. The natural history of the disease is characterized by recurrent relapses and progressively shorter remissions with a median survival of 10yrs. The impossibility of achieving a definite cure, have prompted investigations into the possible role of more active and less toxic strategies with innovative therapeutic agents.
Recently Casulo et al. demonstrated that approximately 20% of patients with FL relapse within two years after achieving remission with R-CHOP and have a poor prognosis. It is conceivable that this particularly chemoresistant population would benefit from specifically targeting the biologic and genetic factors that likely contribute to their poor prognosis.
Evolving strategies for difficult to treat FL patients have recently considered immunomodulatory agents, new monoclonal antibodies as well as drugs targeting selective intracellular pathways. The importance of targeting the microenvironment together with the malignant FL cell has been particularly underscored.
We review the most promising approaches, such as combining  anti-CD20 antibodies with immunomodulatory drugs (Lenalidomide),  mAbs directed against other surface antigens such as CD22 and CD23 (Epratuzumab, Lumiliximab), immunomodulatory antibodies such as PD-1, or  inhibitors of key steps in the B-cell receptor pathway signaling such as PI3K inhibitors (Idelalisib, Duvelisib). Another highly attractive approach is the application of the bi-specific T-cell engaging (BiTE) antibody blinatumomab which targets both CD19 and CD3 antigens. Moreover, we highlight the potential of these therapies, taking into account their toxicity. Of course, we must wait for Phase III trials results to confirm the benefit of these new treatment strategies toward a new era of chemotherapy-free treatment for follicular lymphoma.

Introduction

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma and constitutes 15% to 30% of lymphoma diagnoses. Its median survival is approaching ten years. The natural history of the disease is characterized by recurrent relapses and progressively shorter remissions. The impossibility of achieving a definite cure using the currently available chemo-immunotherapy regimens, as well as with more intensive treatments, such as high-dose therapy plus stem cell transplantation, have prompted investigations into the possible role of innovative therapeutic agents with more activity and less adverse events. Avoiding the toxic effects of chemotherapy would also be desirable for a disease with a relatively indolent course, where quality of-life is of primary importance, particularly in the elderly population.[1]

In addition, there are subsets of FL patients with a more aggressive disease who would also benefit from alternative treatment strategies. Recently, the US National LymphoCare Study have published data which show that approximately 20% of patients with FL relapse within two years from achieving remission with R-CHOP and have a poor prognosis, independent of that predicted by the FL International Prognostic Index (FLIPI). Their 5-year overall survival (OS) was only 50% compared to 90% in patients who had a longer treatment response.[2]

It is conceivable that this particularly chemo-resistant population would benefit from specifically targeting the biologic and genetic factors that likely contribute to the poor prognosis of this group. Indeed, the biological characteristics of FL and, more importantly, of its microenvironment, significantly impact on prognosis and may also play a significant role in determining FL sensitivity to treatments. A gene expression signature of the non-malignant stromal cells has been reported; that was prognostically more important than gene signatures deriving from the neoplastic B-cells.[3]

More recently, Pastore et Al. found that mutations in seven genes (EZH2, ARID1A, MEF2B, EP300, FOXO1, CREBBP, and CARD11), coupled with clinical parameters of FLIPI score and Eastern Cooperative Oncology Group (ECOG) performance status, were able to identify subgroups of FL patients with a distinct worse prognosis. This clinicogenetic risk model was termed m7-FLIPI.[4]

With the expanding knowledge of the pathogenesis of B-cell malignancies, in the last few years, several new therapies acting through a variety of mechanisms have shown promising results. We will briefly review the evidence available on these new drugs, which include new monoclonal antibodies and immunoconjugates, the anti-angiogenic and immunomodulatory agent lenalidomide, inhibitors of B-cell receptor pathway enzymes, such as ibrutinib, idelalisib, duvelisib and TGR-1202, BCL2 inhibitors, checkpoint inhibitors and CAR-Tcells (Table 1).


Table 1 Table 1


New Generation mAbs

AntiCD20 mAbs: The search for a monoclonal antibody with a higher activity than rituximab has been particularly active in recent years.

Ofatumumab is a humanized, class I anti-CD20 agent with an increased complement dependent cytotoxicity compared with rituximab. It binds to a different CD20 epitope resulting in higher affinity and, theoretically, a higher activity in cases with low CD20 surface expression.[5] In a phase 3 trial including 116 FL patients previously treated with rituximab or rituximab-containing chemotherapy, ofatumumab monotherapy was well tolerated, but it showed an overall response rate (ORR) of only 10% in the 86 patients who received the highest dose (1000 mg/8 weekly doses).[6] However, in first-line, in a phase 2 trial of FL patients, ofatumumab,  given at 1000mg per week for a month and subsequently 1000 mg every 2 months for 8 months, obtained an ORR of 86% (Complete response [CR] in 13%) with a 1-year PFS probability of 97% and a safety profile similar to rituximab.[7] It has also been administered as part of combination treatment; 59 patients with advanced-stage, previously untreated FL received ofatumumab plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and attained an ORR of 100%, with CR in 62% of patients.[8]

Obinutuzumab (GA101) is another humanized anti-CD20 agent. It is a class II agent, and therefore, it has a higher antibody-dependent cellular cytotoxicity and induces B-lymphocyte apoptosis more effectively than rituximab.[9]

In patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL), eight cycles of obinutuzumab were administered (days 1 and 8 of the first cycle and day 1 of each subsequent cycle).[10] One arm received 1600 mg in the first cycle and 800 mg subsequently, while the other arm received 400 mg (flat dose), obtaining an ORR of 55% and 17% and a median PFS of 11.9 and 6 months, respectively. In a phase II study including R/R iNHL patients, an induction and maintenance courses of obinutuzumab (4 weekly doses of 1000 mg and then every 2 months for 2 years) were superior in terms of ORR (45% vs. 27%) but not PFS to induction and maintenance with rituximab at the standard 375 mg/m2.[11]

GADOLIN (NCT01059630) is a phase 3 study including 396 rituximab-refractory iNHL patients. This randomized trial compared bendamustine alone (120 mg/m2 on days 1 and 2 of every 28-day cycle for up to six cycles) with bendamustine (90mg/m2) combined with obinutuzumab (1000 mg on day 1 of every cycle and days 8 and 15 of the first cycle), followed by maintenance with obinutuzumab.  Both arms obtained the same ORR (63% vs. 69%), but a longer PFS was seen with the combination regimen followed by maintenance in the 321 patients (81%) with FL (13.8 months vs. not reached, Hazard ratio 0.48 [0.34-0.68]), despite a similar OS at the time of first analysis (albeit with less than 2 years of follow-up).[12] Obinutuzumab-bendamustine was slightly more toxic, particularly due to an increased frequency of neutropenia (grade≥3 in 33%) and infusion reactions (grade≥3 in 8%), although there were fewer episodes of pneumonia (3%) and less thrombocytopenia (grade≥3 in 10%) than in the bendamustine monotherapy arm.

To date, the final results of the GAUSS Study, in which obinutuzumab (GA101) was prospectively compared with rituximab in a randomized fashion in relapsed indolent lymphoma, have been published.[13] Among patients with follicular lymphoma, ORR seemed higher for obinutuzumab than rituximab (44.6% v 33.3%; P .08). However, this difference did not translate into an improvement in progression-free survival. No new safety signals were observed for obinutuzumab, and the incidence of adverse events was balanced between arms, with the exception of infusion-related reactions and cough, which were higher in the obinutuzumab arm.   

The use of obinutuzumab in first-line therapy is under investigation, recruitment has been completed for the GALLIUM study (NCT01332968), a phase 3 randomized trial, including 1400 patients with previously untreated iNHL, comparing obinutuzumab vs. rituximab with combination chemotherapy. The results are still unpublished, but the interim analysis seems positive.

Other B-lineage antigen-directed antibodies: Although targeting CD22 and CD23 by antibodies such as epratuzumab or lumiliximab was less successful when applied to single agents,[14] the combination of epratuzumab with rituximab induced significant response rates both in relapse and front-line therapy.[15] A similar activity was found when the CD22 antibody inotuzumab was conjugated with ozogamicin and its combination with rituximab.[16] Promising data were also achieved by combining the anti-CD 80 antibody Galiximab with rituximab in patients with untreated FL.[17]

However, most of the above mentioned agents did not show sufficient activity to be further developed beyond the stage of clinical phase II studies.

More recently an anti-CD79B antibody has been successfully fused with the microtubule-disrupting agent monomethyl auristatin E. The resulting antibody-drug conjugate polatuzumab vedotin has undergone phase 1 and preliminary phase 2 studies and is currently under further investigation.[18]

Drugs Targeting Oncogenic Pathways

PI3K Inhibition: PI3K are enzymes involved in cell cycle regulation, apoptosis, DNA repair, senescence, angiogenesis and cell metabolism. Through their activation, cell surface signals are transmitted into the cytoplasm and, by phosphorylating different downstream molecules, they activate pathways such as BTK, AKT, PKC, NF-kappa-B and JNK/SAPK, which ultimately result in cell survival and growth. Its specific targeting has a strong rationale, given the interplay between lymphoma and microenvironment in FL. Different PI3K isoforms can be found in different cell types.[19]
Idelalisib is the first orally bioavailable, active inhibitor specifically targeting the delta isoform of PI3K, an enzyme downstream from the B cell receptor, which eventually signals through AKT and mTOR.[20] Idelalisib showed marked antitumor activity in patients with FL who had not had a response to rituximab and an alkylating agent or had had a relapse within six months after those therapies (double-refractory patients). In a single-arm, open-label, phase 2 study, 125 patients with indolent non-Hodgkin’s Lymphomas were enrolled, including 72 FL patients refractory both to chemotherapy and rituximab.[21] They received idelalisib, 150 mg twice daily, until disease progression. The 57% response rate was much higher compared to historical rituximab[22] results in the same setting of refractory patients, with 14% meeting the criteria for a complete response. The median time to response was 1.9 months, the median duration of response was 12.5 months, and the median progression-free survival was 11 months. The most common adverse events of grade 3 or higher were neutropenia, in 27% of the patients, elevations in aminotransferase levels in 13%, diarrhea in 13%, and pneumonia in 7%).[21]
The results of this study led to the approval of idelalisib by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of FL relapsed after two previous lines of treatment (in the case of the EMA approval, refractoriness to the two previous lines of therapy is required).
However, because of an excess of severe infections, including Cytomegalovirus reactivation and Pneumocystis jirovecii pneumonia, in the idelalisib arm of three randomized trials, the safety of idelalisib particularly in the first line setting, is currently under reevaluation. Moreover, the association of idelalisib with lenalidomide and rituximab caused prohibitive hepatic toxicity in a phase I-II trial which had to be interrupted,[23] underscoring the importance of an accurate evaluation of the risk benefit ratio of any new or any combination of no cytostatic agents. Other PI3k inhibitors currently under investigation include TGR-1202, duvelisib, and copanlisib.
TGR-1202 is, like idelalisib, a selective delta isoform inhibitor. However, unlike the later, it showed very few autoimmune- mediated side effects in a recent analysis of 152 highly pretreated patients with CLL and NHL receiving TGR-1202 in monotherapy or in combination with the new anti-CD20 ublituximab.[24] In the subgroup of R/R iNHL, the ORR was 49% in monotherapy and 71% (CR in 24%) when administered in combination.
Duvelisib (IPI-145), a gamma and delta isoform inhibitor, showed an ORR of 65% in a phase 1 dose-escalation study in patients with iNHL,[25] which successfully met the primary endpoint of the phase II DYNAMO study.
The phase II study enrolled 129 patients with iNHL, which included follicular lymphoma (n=83), small lymphocytic leukemia (SLL; n=28), and marginal zone lymphoma (MZL; n=18). The ORRs in each of these groups, respectively, were 41%, 68%, and 33%. The majority of adverse events reported in the study were labeled as clinically manageable and reversible.
Despite achieving the primary endpoint of the study, the magnitude of benefit did not match Infinity's expectations. Based on the results, the long-term outlook for the medication was adjusted, studies exploring duvelisib in combination with venetoclax were paused, and 21% of the organization's workforce was laid off as part of a research and development restructuring.[26]
Copanlisib, which inhibits the alfa and the delta isoform of PI3k, is also under active investigation and results of ongoing trials with this intravenously compound are awaited. To date, it seems to interfere with glucose metabolism.

Bruton tyrosine kinase pathway inhibitors: The BTK pathway represents a further very attractive target in B-cell malignancies. Ibrutinib is the first-in-class among specific BTK-inhibitors.[27]
In R/R FL, in an update of the initial dose- escalation trial, ibrutinib monotherapy administered once daily at the dose of 560 mg until progression or withdrawal, has shown an ORR of 63% (CR in 38%) and a median PFS of 24 months. Among refractory NHL of different histologic subtypes, only minor activity was shown in patients with FL in contrast with patients with mantle cell lymphoma or Waldenstrom Macroglobulinemia, where results were much more promising.[28] The combination of ibrutinib with chemoimmunotherapy (ICT) as well as with other agents including the combination of lenalidomide and rituximab is currently being tested. The preliminary results of a phase I-Ib study of the combination of ibrutinib with bendamustine and rituximab do not seem to confer a significant advantage over BR alone, but the number of patients treated was small.[29]
Phase 3 studies, such as SELENE (NCT01974440), which randomizes patients with R/R FL or marginal zone lymphoma to ICT (BR or RCHOP) with or without ibrutinib, are also underway.

Bcl 2 inhibitors: Interesting data also emerged from agents interfering with the BCL2 family of proteins.
BCL2 is an antiapoptotic protein, typically overexpressed in lymphoma by the presence of its characteristic translocation t(14;18), which involves the BCL2 gene. However, anti-BCL2 drugs are proving active in a wide variety of B-cell disorders.[30]
Promising response rates were initially reported from a phase 1 study with ABT-263 (navitoclax), which is, however, associated with thrombocytopenia.[31] A better efficacy-toxicity profile is revealed by the BH3 mimetic ABT-199 (venetoclax), already approved by FDA for B-CLL, which, in a phase 1 study, showed an ORR of 48% as a single agent. Given the direct involvement of bcl-2 in the pathogenesis of FL, the results achieved may be considered less favourable than expected. However, owing to its good tolerability profile, the combination of venetoclax with chemoimmunotherapy or other active agents is actively investigated and may yield better results.[32] A phase 1b/2 trial with venetoclax, obinutuzumab and polatuzumab vedotin (NCT02611323) in R/R FL is currently recruiting patients. Trials with obatoclax, another BCL2 inhibitor, are also ongoing (NCT00438178, NCT00427856), but no results are available.

M-TOR inhibitors and histone-deacetylase inhibitors: Temsirolimus is a mammalian target of rapamycin (mTOR) inhibitor, approved for the treatment of MCL, but which has also shown activity in FL. In 39 patients with R/R FL, at a weekly dose of 25 mg (intravenously), temsirolimus achieved an ORR of 54% (CR in 24%) and 3-year PFS and OS probabilities of 26% and 72%, respectively. Grade ≥3 neutropenia and thrombocytopenia were seen in around 30% of patients with all other toxicities, grade ≥3, occurring in ≤6% of patients.[33] Temsirolimus is currently undergoing phase 3 trials in association with bendamustine and rituximab by the German study group.
The histone deacetylase inhibitor vorinostat has been studied in a phase II study in relapsed indolent lymphomas, which included 39 patients with FL, and demonstrated an encouraging 49% overall response rate with a median progression-free survival of 20 months in this small cohort.[34]
Everolimus too showed promising results in the relapsed/refractory setting with an ORR of 84 and 60%.[35] 

Immunomodulatory Drugs (IMiD)

Lenalidomide is one of the most promising new agents in the treatment of FL. Its mechanism of action is not fully understood but probably includes a modulation of the lymphoma microenvironment and an enhanced anti-lymphoma immune response.[36] After promising single-agent activity was seen particularly in patients with refractoriness to prior therapies (ORR 23%, the median time to antitumor response 3.6 months, median PFS 4.4 months).[37]
Lenalidomide was combined with rituximab in the so-called R-squared or R2 regimen. The combination showed a higher ORR (76% vs. 53%) and longer time to progression (2 vs. 1.1 years), with no increased toxicity than lenalidomide alone.[38] In the front-line setting, two recent publications reported results of phase 2 trials with the R-squared scheme. In the first, ORR was 98% (CR in 87%) with a 3-year PFS probability of 78% in a sub- group of 50 FL patients (out of 110 iNHL patients).[39] The second trial carried out by the CALGB revealed an ORR of 93% (CR in 72%) and a 2-year PFS probability of 89% in 65 FL patients of whom only two discontinued treatment due to progressive disease and four due to toxicity.[40]
The same regimen has been subsequently compared with standard chemoimmunotherapy in a randomized phase 3 study (RELEVANCE) in untreated patients. Both arms are followed by a maintenance phase. Accrual has been completed but results are still not available.[41]

Anti PD-1: Follicular lymphoma is characterized by a significant interplay between malignant cells and their microenvironment.[42]
PD-1 is a T-cell receptor which, upon binding its ligand (PD-L1 or PD-L2, found on B-cells), blunts T-cell response. PD-1 expression is an escape mechanism for a variety of solid and hematologic malignancies.[43]
The observation that some FL patients might have a very long survival without progressive disease after diagnosis and do not need anti-lymphoma therapy for years underscores the potential role of the activity of the immune system against the lymphoma cells. Although FL CD20+ tumor cells do not directly express PD1 ligands, PD-L1+ histiocytes are present within the T-cell-rich zone of the neoplastic follicles and contribute to the exhaustion of tumor PD1+ infiltrating T cells. Therefore, this subtype of lymphoma may represent a candidate for inhibiting the PD1–PD1-ligand axis.[44]
In a phase 1, open-label,  single agent dose-escalation study, Nivolumab, an anti-PD1–blocking IgG4 antibody with higher affinity, yielded a response rate of 40% in 10 patients with relapsed/refractory FL, with a complete response rate of 10%, lending support to the importance of immune surveillance in the control and progression of this disease.[45]
Pidilizumab is an IgG1 isotype anti-PD1 antibody with lower affinity than other anti-PD-1 immune-checkpoint inhibitors. In 2014, the first results of a single group, phase 2 trial of pidilizumab combined with rituximab in relapsing follicular lymphoma were published. This combination showed a high objective response (66%) and complete response (52%,) with a median progression-free survival of 18・8 months (95% CI 14・7–not reached), an improvement on the expected results of rituximab alone in the same setting.  No adverse events of grade 3-4 were reported.[46]
Although the actual benefit of this combination has to be established in a randomised study, these findings suggest that pidilizumab might enhance antitumor immune responses. The investigators correlated baseline gene expression signatures in tumor biopsy samples of 18 patients with the outcome of anti-PD1 therapy. They showed that a prominent T-cell activation signature or a signature of genes repressed in regulatory T cells were significantly associated with prolonged progression-free survival. Of major interest was the finding that a drug specifically targeting the immune system (pidilizumab) could be combined with drugs directly targeting the pathological cells (rituximab) to improve results.
To date, several trials with other checkpoint inhibitors such as ipilimumab, an anti-CTLA-4 (NCT01592370), and pembrolizumab, another PD-1 inhibitor, (NCT02446457), are ongoing.

Bispecific T-cell Engagers and CAR-T Cells

Combining the specific targeting of the FL neoplastic cells obtained by mAb with the recruitment and activation of immune cells may ultimately be the most efficient strategy to achieve the definitive cure of FL.
A highly attractive approach is the application of the bi-specific T-cell engaging (BiTE) antibody blinatumomab which targets both CD19 and CD3 antigens. Although the development of this BiTE antibody is currently focused on B-precursor acute lymphoblastic leukemia, promising, early results were also obtained in B-cell lymphomas, where single agent blinatumomab at the dose of 60 ug/m2/day achieved an ORR of 80% in heavily pretreated FL patients, although with significant neurotoxicity with encephalopathy.[47] Expanding clinical experience with the use of these molecule has reduced the important side effects initially observed. Moreover, subcutaneous formulations of blinatumumab have been developed and are currently being tested to allow its easier use in patients with lymphoma. 

Chimeric antigen receptor (CAR)-modified T cells have generated broad interest in oncology following a series of dramatic clinical successes in patients with chemorefractory B cell malignancies. CAR therapy now appears to be on the cusp of regulatory approval as a cell-based immunotherapy.
Following a decade of preclinical optimization, CD19 chimeric antigen receptor (CAR) therapy has rapidly made a high impact in oncology. Within a few years, the CAR field has progressed from reports of anecdotal responses in patients with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL) to achieving reproducible outcomes in hundreds of patients with B cell malignancies, most strikingly in B cell acute lymphoblastic leukemia (B-ALL), including patients with chemotherapy-refractory disease.[48] Indeed, the antitumor activity of anti-CD19 CAR was first reported in a case of advanced follicular NHL, in which anti-CD19 CAR therapy resulted in dramatic regression. Peripheral blood B-cells were absent for at least 39 weeks after treatment, but no acute toxicities occurred.[49]  
This field is rapidly expanding both in the molecular engineering of new and more active products and in their clinical application in different hematological malignancies, including cases of FL.[50] Nevertheless, the reproducibility and feasibility of CAR-T cell therapy on a scale broad enough to be offered to a large population of patients with CD19-positive malignancies need to be adequately demonstrated in more extensive studies.
The results of autologous CD19-targeted second-generation CAR T cells treatment obtained so far in indolent NHL patients have been recently updated.[51] Of 15 patients enrolled, eight achieved complete remissions (CRs), four achieved partial remissions, one had stable lymphoma, and two were not evaluable for response. CRs were obtained by four of seven evaluable patients with chemotherapy-refractory DLBCL; three of these four CRs are ongoing, with durations ranging from 9 to 22 months. Acute toxicities including fever, hypotension, delirium, and other neurologic toxicities occurred in some patients after infusion of anti-CD19 CAR T cells; these toxicities resolved within three weeks after cell infusion. One patient died suddenly as a result of an unknown cause 16 days after cell infusion. The most troublesome toxicities experienced by patients were hypotension and neurologic toxicities. The mechanism of these neurologic toxicities is not entirely known. Elevated levels of interferon gamma and of interleukin-6 but not of tumor necrosis factor-alfa were common. Importantly, all patients recovered completely from their neurologic toxicities. Some of the neurologic toxicities observed were similar to toxicities observed in other trials of anti-CD19 CAR T cells and clinical trials of anti-CD19– and anti-CD3–bispecific antibodies. 

In conclusion, in the last few years, several targeted drugs have shown activity in FL. Some of them like lenalidomide, selected PI3k inhibitors, and several new anti CD-20 monoclonal antibodies are likely to enter the clinical arena soon. Other compounds are still under clinical evaluation, like  BTK-inhibitors, anti-bcl-2, and immunotoxins, whereas highly promising approaches, such as CART-cells and bispecific antibodies, need additional investigations to define their activity/toxicity and their best place in the treatment strategy for FL. All together they will certainly further expand our therapeutic armamentarium for FL patients including the highly refractory population that still has a dismal prognosis and no therapeutic options.
However, we must highlight that “chemo-free” treatments are not “toxicity-free,” which means that despite a different safety profile from that of the standard immunochemotherapy regimens, these new therapies continue to present significant and still incompletely known toxicities. The major trials, especially in the front-line setting and with combinations of different agents, have a limited follow-up period and involve relatively small patient populations. Thus, caution must be exercised in the interpretation of their results and only time will tell if they will ultimately replace our standard therapeutic approaches.
To conclude, we believe that the real challenge in the near future will be how to optimize and integrate in the clinical practice the results of the many studies reported, with the goal of achieving the cure of FL without compromising the quality of life of our patients. A further challenge, whose discussion is beyond the scope of the present review, will be how to optimize treatments also from an economic perspective. Given the high costs of all the novel agents described, the sustainability of every treatment program based on their use is likely to become equally important as their efficacy.  

References

  1. Ujjani C., Cheson BD The current status and future impact of targeted therapies in non-Hodgkin lymphoma. Expert Rev Hematol 2013; 6: 191-202. http://dx.doi.org/10.1586/ehm.13.6 PMid:23547867        
  2. Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, Hainsworth JD,Maurer MJ, Cerhan JR, Link BK, Zelenetz AD, Friedberg JW. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. J Clin Oncol. 2015 Aug 10; 33(23):2516-22. http://dx.doi.org/10.1200/JCO.2014.59.7534 PMid:26124482 PMCid:PMC4879714     
  3. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD et Al. Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells. N Engl J Med. 2004; 351(21):2159-2169 http://dx.doi.org/10.1056/NEJMoa041869 PMid:15548776        
  4. Pastore A, Jurinovic V, Kridel R, Hoster E, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015 Sep; 16(9):1111-22. Epub 2015 Aug 6. http://dx.doi.org/10.1016/S1470-2045(15)00169-2     
  5. S. Herter, Herting F, Mundigl O, Waldhauer I et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models, Mol. Cancer Ther. 12 (2013) 2031-2042, 7. http://dx.doi.org/10.1158/1535-7163.MCT-12-1182 PMid:23873847        
  6. M.S. Czuczman, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study, Blood 119 (2012) 3698-3704. http://dx.doi.org/10.1182/blood-2011-09-378323 PMid:22389254        
  7. C.A. Rosenbaum, et al. Phase, Trial of ofatumumab (OFA) in previously untreated follicular non-Hodgkin lymphoma (NHL): CALGB 50901 (Alliance), Blood 126 (2015) 2741.      
  8. M.S. Czuczman, Fayad L, Delwail V, Cartron G et al. Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma, Br. J. Haematol. 157 (2012) 438-445. http://dx.doi.org/10.1111/j.1365-2141.2012.09086.x PMid:22409295        
  9. G.A. Salles, Morschhauser F, Solal-Céligny P, Thieblemont Cet al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study, J. Clin. Oncol. 31 (2013) 2920-2926. http://dx.doi.org/10.1200/JCO.2012.46.9718 PMid:23835715        
  10. L.H. Sehn, Goy A, Offner FC, Martinelli G et al. Randomized Phase, Trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-Cell non-Hodgkin lymphoma: final analysis of the GAUSS study, J. Clin. Oncol. 33 (2015) 3467-3474. http://dx.doi.org/10.1200/JCO.2014.59.2139 PMid:26282650        
  11. L.H. Sehn, et al. GADOLIN: primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma, J. Clin. Oncol. (2015) (33S:LBA8502).     
  12. L.H. Sehn, Chua N, Mayer J, Dueck G et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial, Lancet Oncol. (2016), 2016 Aug;17(8):1081-93. Epub 2016 Jun 23. http://dx.doi.org/10.1016/S1470-2045(16)30097-3       
  13. Trnený M, Bouabdallah K, Dueck G, Gribben G et Al. Obinutuzumab plus bendamustine versus bendamustine alone in patients with rituximab-refractory follicular lymphoma: results from the GADOLIN study. Haematologica (EHA. Annual Meeting Abstracts), 2016, 101, S440, pag. 155.
  14. Leonard JP, Coleman M, Ketas JC, Chadburn A et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3051-9. http://dx.doi.org/10.1200/JCO.2003.01.082 PMid:12837807        
  15. Grant B, et al. Combination biologic therapy as initial treatment for follicular lymphoma: initial results from CALGB 50701-a phase II trial of extended induction epratuzumab (anti-CD22) and rituximab (anti-CD20). Blood (ASH annual meeting abstracts). 2010;116: (Abstract 430).
  16. Goy A, et al. Inotuzumab ozogamicin (CMC-544) in patients with indolent B-cell NHL that is refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy: preliminary safety and efficacy from a phase 2 trial. Blood (ASH annual meeting abstracts). 2010;116: (Abstract 427).
  17. Leonard J, Friedberg JW, Younes A, Fisher D et al. A phase I/II study of galiximab (an anti CD-80 monoclonal antibody) in combination with rituximab for relapsed or refractory follicular lymphoma. Ann Oncol 2007;18: 1216-23 http://dx.doi.org/10.1093/annonc/mdm114 PMid:17470451      
  18. Palanca-Wassels M, et al. A phase I study of the anti-CD79b in relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). Blood (ASH annual meeting abstracts). 2012;120: (Abstract 56).     
  19. Flinn, I.W. Kahl BS, Leonard JP, Furman RR et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- , as therapy for previously treated indolent non-Hodgkin lymphoma, Blood 123 (2014) 3406-3413. http://dx.doi.org/10.1182/blood-2013-11-538546 PMid:24615776 PMCid:PMC4260978     
  20. Hewett YG, Uprety D, Shah BK. Idelalisib- a PI3Kd targeting agent for B-cell malignancies. J Oncol Pharm Pract. 2016 Apr;22(2):284-8. Review. http://dx.doi.org/10.1177/1078155215572933      
  21. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND et al. PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014 Mar 13; 370(11):1008-18. http://dx.doi.org/10.1056/NEJMoa1314583 PMid:24450858 PMCid:PMC4039496     
  22. Davis TA, Maloney DG, Grillo-López AJ, White CA, Williams ME, Weiner GJ,Dowden S, Levy R. Combination immunotherapy of relapsed or refractory low-gradeor follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res. 2000 Jul;6(7):2644-52. PMid:10914705        
  23. Cheah CY, Nastoupil LJ, Neelapu SS, Forbes SG et al. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood. 2015 ; 125(21):3357-9. http://dx.doi.org/10.1182/blood-2015-03-633156      
  24. O’Connor O.A., Flinn I, Lunning M, Vose J et al. Long-term follow-up of the next generation PI3K-delta inhibitor TGR-1202 demonstrates safety and high response rates in NHL: integrated-analysis of TGR-1202 monotherapy and combined with ublituximab, Haematologica 101 (2016) 102-103, abstract P315.     
  25. Flinn I, Oki Y, Patel M, Horwitz SM et al. A phase 1 evaluation of duvelisib (IPI-145), a PI3K-, inhibitor, in patients with relapsed/refractory iNHL, Blood 124 (2014) 802.     
  26. Infinity Reports Topline Results From DYNAMO™, A Phase 2 Monotherapy Study Of Investigational Molecule Duvelisib In Refractory Indolent Non-Hodgkin Lymphoma. CAMBRIDGE, Mass., June 14, 2016 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) http://www.infi.com/ 
  27. Honigberg LA, Smith AM, Sirisawad M, Verner E et al. The BrutonTyrosine kinase inhibitor (PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Nati Acad Sci USA 2010; 107: 13075-80. http://dx.doi.org/10.1073/pnas.1004594107 PMid:20615965 PMCid:PMC2919935     
  28. Fowler N, Boyd TE, Sharman JP., Sonali M et al. Long-term follow-up and analysis of dose groups with ibrutinib in relapsed follicular lymphoma, Blood 126 (2015) 2706.     
  29. Maddocks K, Christian B, Jaglowski S, Flynn J et al. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Blood. 2015 Jan 8;125(2):242-8Epub 2014 Oct 29 http://dx.doi.org/10.1182/blood-2014-08-597914      
  30. Gerecitano JF, Roberts AV, Seymour GF et al. A phase 1 study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma, Blood 126 (2015) 254     
  31. Kahl B, Roberts AW, Seymour JF, Advani RH et al. Navitoclax (ABT-263) plus rituximab: Interim results of a phase I study in patients with CD 20-positive lymphoid malignancies. Blood 2010; 116: 3943.     
  32. Davids MS, RobertsAW, Anderson MA, Pagel JM et al. The bcl2 specific BH3-mimetic ABT-199 (GDC-0199) is active and well tolerated in patients with relapsed non-Hodgkin lymphoma: interim results of a phase I study. Blood 2012; 120: 304.     
  33. S.M. Smith, van Besien K, Karrison T, Dancey J et al. Temsirolimus has activity in non-mantle cell non-Hodgkin’s lymphoma subtypes: the University of Chicago phase II consortium, J. Clin. Oncol. 28 (2010) 4740-4746. http://dx.doi.org/10.1200/JCO.2010.29.2813 PMid:20837940 PMCid:PMC3020703     
  34. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M et al. Phase III study to evaluate temsirolimus compared with investigator’s choicetherapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 3822-3829. http://dx.doi.org/10.1200/JCO.2008.20.7977 PMid:19581539        
  35. Kirschbaum M, Frankel P, Popplewell L, Zain J et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2011 20;29(9):1198-203. http://dx.doi.org/10.1200/JCO.2010.32.1398      
  36. Witzig TE, Reeder CB, LaPlant BR, Gupta M et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukaemia 2011; 25: 341-347 .http://dx.doi.org/10.1038/leu.2010.226 PMid:21135857 PMCid:PMC3049870     
  37. Chanan-Khan AA, Cheson BD et al. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008; 26: 1544-1552. http://dx.doi.org/10.1200/JCO.2007.14.5367 PMid:18285605        
  38. Witzig TE, Wiernik PH, Moore T, Reeder C et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s Lymphoma. J Clin Oncol 2009; 27: 5404-5409. http://dx.doi.org/10.1200/JCO.2008.21.1169 PMid:19805688        
  39. Leonard JP, Jung SH, Johnson J, Pitcher BN et al. Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). J Clin Oncol. 2015 Nov 1;33(31):3635-40. http://dx.doi.org/10.1200/JCO.2014.59.9258 PMid:26304886        
  40. Fowler NH, Davis RE, Rawal S, Nastoupil L et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014;15(12):1311-8.. Epub 2014 Oct 15. http://dx.doi.org/10.1016/S1470-2045(14)70455-3      
  41. Martin, Jung, S.H., Johnson, J.L., Pitcher et al. CALGB 50803 (Alliance): a phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma, J. Clin. Oncol. (2014), 32S. 8521.    
  42. Neelapu SS. Mutations and microenvironment collude in FL. Blood 2015 125:587-589; http://dx.doi.org/10.1182/blood-2014-12-615294      
  43. Armand P. Immune checkpoint blockade in hematologic malignancies, Blood 2015 125:3393-3400; doi:10.1182/blood-2015-02-567453 http://dx.doi.org/10.1182/blood-2015-02-567453      
  44. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T et al. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 2001; 98: 13866-71. http://dx.doi.org/10.1073/pnas.231486598 PMid:11698646 PMCid:PMC61133     
  45. Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A et al. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol. 2016 ;34(23):2698-704. http://dx.doi.org/10.1200/JCO.2015.65.9789      
  46. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single-group, open-label, phase 2 trial. Lancet Oncol 2014; 15(1): 69-77. http://dx.doi.org/10.1016/S1470-2045(13)70551-5      
  47. Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS et al. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. J Clin Oncol. 2016 Apr 1;34(10):1104-11. Epub 2016 Feb 16, http://dx.doi.org/10.1200/JCO.2014.59.1586     
  48. M Davil, Sadelain M. Biology and clinical application of CAR-T cells for B cell malignancies. Int J Hematol. 2016 Jul;104(1):6-17. Review http://dx.doi.org/10.1007/s12185-016-2039-6      
  49. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010 Nov 18;116(20):4099-102. http://dx.doi.org/10.1182/blood-2010-04-281931      
  50. Onea AS, Jazirehi AR. CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas. Am J Cancer Res. 2016 Jan 15;6(2):403-24. PMid:27186412 PMCid:PMC4859669     
  51. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignan- cies can be effectively treated with autologous T cells express- ing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540-9. http://dx.doi.org/10.1200/JCO.2014.56.2025 PMid:25154820 PMCid:PMC4322257    

[TOP]

Abstract views:
1095

Views:
PDF
327
HTML
553

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

The Mediterranean Journal of Hematology and Infectious Diseases [eISSN 2035-3006] is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.
 
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185